- Home
- AGL vs CGON Comparison
AGL vs CGON Comparison
Compare AGL & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGL
- CGON
- Stock Information
- Founded
- AGL 2016
- CGON 2010
- Country
- AGL United States
- CGON United States
- Employees
- AGL 1076
- CGON N/A
- Industry
- AGL Managed Health Care
- CGON
- Sector
- AGL Health Care
- CGON
- Exchange
- AGL Nasdaq
- CGON NYSE
- Market Cap
- AGL 1.4B
- CGON 1.3B
- IPO Year
- AGL 2021
- CGON 2024
- Fundamental
- Price
- AGL $2.50
- CGON $24.88
- Analyst Decision
- AGL Hold
- CGON Strong Buy
- Analyst Count
- AGL 21
- CGON 11
- Target Price
- AGL $4.59
- CGON $62.90
- AVG Volume (30 Days)
- AGL 6.2M
- CGON 2.0M
- Earning Date
- AGL 05-06-2025
- CGON 05-13-2025
- Dividend Yield
- AGL N/A
- CGON N/A
- EPS Growth
- AGL N/A
- CGON N/A
- EPS
- AGL N/A
- CGON N/A
- Revenue
- AGL $5,988,958,000.00
- CGON $662,000.00
- Revenue This Year
- AGL N/A
- CGON N/A
- Revenue Next Year
- AGL $10.63
- CGON $13,724.75
- P/E Ratio
- AGL N/A
- CGON N/A
- Revenue Growth
- AGL 23.07
- CGON 224.51
- 52 Week Low
- AGL $1.50
- CGON $14.80
- 52 Week High
- AGL $7.73
- CGON $40.47
- Technical
- Relative Strength Index (RSI)
- AGL 30.62
- CGON 50.99
- Support Level
- AGL $3.71
- CGON $23.32
- Resistance Level
- AGL $4.78
- CGON $25.81
- Average True Range (ATR)
- AGL 0.37
- CGON 2.31
- MACD
- AGL -0.16
- CGON -0.05
- Stochastic Oscillator
- AGL 0.63
- CGON 28.50
About AGL agilon health inc.
Agilon Health Inc is transforming healthcare by empowering primary care physicians for the health of the patients. The company enables physicians to create their own Medicare-centric globally capitated line of business. The company derives its revenue from Medical services.
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.